An interventional study of Dexmedetomidin and Esketamine in Emergence Agitation and Vocal Cord Polyps, sponsored by The First Hospital of Jilin University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by The First Hospital of Jilin University · Not applicable, Interventional, and Treatment
This is a single-center, prospective, single-blinded, randomized controlled trial conducted at The First Hospital of Jilin University. A total of 134 adult patients aged 18-65 years with ASA Ⅰ-Ⅲ undergoing elective laryngoscopic surgery for vocal cord polyps will be enrolled. Subjects will be randomly assigned into two groups. The control group receives intranasal dexmedetomidine plus intravenous normal saline before anesthesia induction. The combination group receives the same dose of intranasal dexmedetomidine plus intravenous esketamine before induction. The primary objective is to compare the incidence of emergence agitation within 60 minutes after extubation. Secondary outcomes include hemodynamic changes, adverse events, recovery time, PACU stay, postoperative sore throat pain and quality of recovery at 24 hours. Standardized anesthesia induction and maintenance will be applied for all patients. The study aims to explore whether the combination of intranasal dexmedetomidine and esketamine improves recovery quality in patients undergoing suspension laryngoscopy.
788 studies on the registry are indexed under Emergence Delirium; 250 are open to participants now.
This study's planned enrollment of 134 is above the median of 120 across 491 interventional studies indexed under Emergence Delirium.
Browse Emergence Delirium studies →The First Hospital of Jilin University is the lead sponsor of 182 studies on the registry; 94 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Aged 18-65 years, male or female. 2. ASA physical status Ⅰ or Ⅱ. 3. Scheduled for elective surgery under general anesthesia with tracheal intubation.
4. Expected operation duration 30-180 minutes. 5. Able to understand the study content and sign written informed consent voluntarily.
Exclusion Criteria:
Patients receive dexmedetomidine before anesthesia induction.
Drug: Dexmedetomidin
Patients receive dexmedetomidine combined with esketamine before anesthesia induction.
Drug: Dexmedetomidin · Drug: Esketamine
Dexmedetomidine will be administered intravenously before anesthesia induction in both groups.
Esketamine will be administered intravenously before anesthesia induction only in the intervention group.
Incidence of emergence agitation within 60 minutes after surgery
The incidence of emergence agitation evaluated by Ricker Sedation-Agitation Scale (RSAS) within 60 minutes after the end of surgery.
Time frame: 60 minutes after the end of surgery
ncidence of cough during anesthesia induction
The incidence of cough events observed during anesthesia induction.
Time frame: During anesthesia induction
Changes of mean arterial pressure during anesthesia induction
The variation of mean arterial pressure at multiple time points from baseline to 5 minutes after tracheal intubation.
Time frame: From baseline to 5 minutes after tracheal intubation
Incidence of adverse hemodynamic events during induction
The occurrence of hypotension or hypertension events during anesthesia induction.
Time frame: From baseline to 5 min after intubation
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
The First Hospital of Jilin University →